Alk-abello
COPENHAGEN, Denmark, November 16 - GAP will be the largest ever trial to investigate the asthma preventive
effect of specific immunotherapy in children (5-12 years old) with allergic
grass pollen rhinoconjunctivitis, commonly known as 'hay fever'.
